- In July 2026, BioCryst Pharmaceuticals, Inc. appointed David W. Jenkins, MA, PhD, as its first Chief Scientific Officer, reporting to Chief Research and Development Officer Dr. Sandeep Menon to build and lead a research team focused on external innovation and partnerships in rare disease therapies.
- By creating a new CSO role and hiring an executive with extensive external innovation experience from companies like Ipsen, Novartis and AstraZeneca, BioCryst is signaling a deeper commitment to expanding its rare disease pipeline through both internal research and partnered assets.
- We’ll now examine how installing a new Chief Scientific Officer focused on external innovation could reshape BioCryst’s rare disease investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 54 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow
Advertisement
BioCryst Pharmaceuticals Investment Narrative Recap
To own BioCryst, you need to believe ORLADEYO can keep funding a broader rare disease portfolio while new assets gradually reduce single‑drug dependence. The Jenkins CSO hire supports that long term pipeline goal, but it does not materially change the near term focus on ORLADEYO execution and upcoming data from early programs, nor the key risk that heavy R&D and business development spending may not translate into commercially
The recent license agreement granting Neopharmed Gentili rights to navenibart in Europe is closely tied to this external innovation push. While Jenkins concentrates on sourcing and shaping future rare disease assets, the navenibart deal already shows BioCryst working with partners to turn its science into non‑US revenue streams, which could modestly diversify away from ORLADEYO if future milestones and royalties are realized
Yet even with these developments, investors should be aware that the company’s heavy reliance on ORLADEYO leaves it exposed if
Read the full narrative on BioCryst Pharmaceuticals (it’s free!)
BioCryst Pharmaceuticals’ narrative projects $930.1 million revenue and $131.3 million earnings by 2029. This requires 1.6% yearly revenue growth and a $589.3 million earnings increase from -$458.0 million today
Uncover how BioCryst Pharmaceuticals’ forecasts yield a $21.30 fair value, a 124% upside to its current price
Exploring Other Perspectives
While consensus focuses on ORLADEYO and measured pipeline progress, the most optimistic analysts once modeled about US$1.0 billion revenue and US$346.0 million earnings by 2029, so Jenkins’ external innovation remit could either reinforce that diversification story or highlight how uncertain long term pipeline expansion really is
Explore 4 other fair value estimates on BioCryst Pharmaceuticals – why the stock might be worth just $21.00!
Reach Your Own Conclusion
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own
- A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate BioCryst Pharmaceuticals’ overall financial health at a glance.
Want Some Alternatives?
Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:
- We’ve uncovered the 7 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:BCRX
BioCryst Pharmaceuticals
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases
See The Free Research Report
Undervalued with reasonable growth potential
See The Free Research Report
Similar Companies
NasdaqGS:BMRN
BioMarin Pharmaceutical
NasdaqGS:IONS
Ionis Pharmaceuticals
Market Insights
A brand’s strength doesn’t always lastRichard Bowman
What makes a lasting brand?Andrew Legget
Q-Day: The risk the market forgot to repriceRichard Bowman
Advertisement
Weekly Picks
LO
Lou_Baseneseon Optimi Health·about 1 month ago
The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist
Fair Value:US$1158.7% undervalued
32followersusers have followed this narrative
·2commentsusers have commented on this narrative
·6likesusers have liked this narrative
WE
WealthAPon Novo Nordisk·7 months ago
Novo Nordisk (NVO): Is the “Easy Growth” Story Over?
Fair Value:DKK 407.7721.6% undervalued
49followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
VA
ValueInvestingSubstackon Zoetis·about 2 months ago
Zoetis down -50% over the past year
Fair Value:US$92.9220.2% undervalued
15followersusers have followed this narrative
·0commentsusers have commented on this narrative
·7likesusers have liked this narrative
CE
CentryResearchon Centrus Energy·6 days ago
Centrus Energy: The Next Nuclear Bottleneck Isn’t Reactors. It’s Fuel
Fair Value:US$1908.3% undervalued
11followersusers have followed this narrative
·0commentsusers have commented on this narrative
·7likesusers have liked this narrative
RecentlyUpdated Narratives
RE
Reexon Unibap Space Solutions·23 minutes ago
Long-term bet on Europe’s strategic space autonomy (2030–2055)
Fair Value:SEK 36.0176.8% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
AV
Averagemikeon Samsara·about 3 hours ago
Samsara’s Future PE Will Soar to 337.7x and the Future is Bright
Fair Value:US$57.34k99.9% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
JO
John_Ericon ServiceNow·about 6 hours ago
The Company Nobody Brags About
Fair Value:US$266.0164.1% undervalued
31followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·about 1 month ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75029.1% undervalued
102followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
BE
benjamin_lvieqon PayPal Holdings·8 days ago
PayPal: PayPal Doesn’t Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6514.6% undervalued
69followersusers have followed this narrative
·2commentsusers have commented on this narrative
·11likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·about 1 month ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5449.5% undervalued
64followersusers have followed this narrative
·3commentsusers have commented on this narrative
·11likesusers have liked this narrative
